ESC: Adverse Outcomes Increased With Suboptimal Adherence to Aspirin After MI
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 28, 2023 -- Suboptimal adherence to aspirin after myocardial infarction (MI) is associated with an increased risk for recurrent MI, ischemic stroke, or death, according to a study presented at the European Society of Cardiology Congress, held Aug. 25 to 28 in Amsterdam.
Anna Meta Kristensen, M.D., from Bispebjerg and Frederiksberg Hospital in Denmark, and colleagues examined the effectiveness of adherence to long-term aspirin therapy at different timepoints following MI using Danish nationwide registries. Patients aged 40 years and older with a first time MI undergoing percutaneous coronary intervention from 2004 to 2017 who were alive and had stayed adherent to aspirin therapy at one year after the index event were included (40,114 individuals). Adherence to aspirin therapy was assessed as the proportion of days covered (PDC) ≤80 and >80 percent at two, four, six, and eight years after MI.
The researchers found an increase in suboptimal adherence to aspirin from 10 to 19 percent at two and eight years after MI. For both adherence groups, the standardized absolute risk for death, recurrent MI, or ischemic stroke was highest at two years after MI (8.34 and 10.75 percent for PDC >80 and ≤80 percent, respectively). At all timepoints of follow-up, the standardized relative risk for the composite endpoint was significantly higher for patients with PDC ≤80 percent. From four years after MI and onward, there was a trend toward a decreasing protective effect of long-term aspirin therapy, decreasing from 1.40 at four years to 1.20 at eight years after MI.
"The results support current guidelines recommending long-term aspirin after a heart attack," Kristensen said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Delay in Hospital Arrival After Stroke Linked to Social Vulnerability
THURSDAY, May 30, 2024 -- Areas with a high incidence of delay in hospital arrival after ischemic stroke are characterized by increased social vulnerability, according to a study...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.